Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 35-43 , February 2007

Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity

  • Danielle Duffy
    • ,
  • Daniel Rader

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Daniel Rader, The Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA. Tel.: (+1) 215-573-4176; fax: (+1) 215-573-8606.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1050-1738(06)00175-7

doi: 10.1016/j.tcm.2006.11.003

Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 35-43 , February 2007

Article Tools

* Image Usage & Resolution